Treating human disease at the genetic level, by replacing defective genes or adding new genes to enhance native functions, has been a long-standing goal, with the first attempts at gene
The success of chimeric antigen receptor (CAR)-T cell therapy has spurred interest in applying CAR technology to other immune cells in hopes of addressing some known limitations. With their intrinsic
Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological malignancies such as relapsed/refractory acute B-cell lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma.
The promise for cell and gene therapies (CGTs) to revolutionize cancer therapy is immense, yet unlocking their full potential to treat more diseases and improve patient access will depend on
The field of cell and gene therapy (CGT) is undergoing a significant transformation, with a notable shift towards allogeneic platforms. Placing a spotlight on what has been deemed the ‘future
The possibility of allogeneic “off-the-shelf” engineered T cell therapies as an alternative to overcome the limitations of autologous therapies has long been a goal for the industry, with some of
The Human Leukocyte Antigens (HLA) are surface proteins on our cells and tissues serving as a mechanism for the body to distinguish between self and non-self, so our immune system
The simplicity and speed of immunomagnetic cell separation has made it the go-to method for isolating target cell populations since it was pioneered in 1990 by Miltenyi Biotec. The ability
Women’s History Month is celebrated every year in March to recognize and honor the contributions and achievements of women throughout history. The 2023 National Women’s History theme is “Celebrating Women
Is The Industry Prepared for Another Year of Rapid Growth? The cell and gene therapy (CGT) industry is expected to grow rapidly for the next 10 years with an increasing
Copyright ©
AllCells. All rights reserved.
